January 27, 2017
Bloomberg BNA
On January 26, 2017 the Federal Circuit ruled in favor of Finnegan client Cumberland Pharmaceuticals, affirming a lower court ruling that rejected Mylan Institutional's claim that the Food and Drug Administration (FDA) was the source of the invention leading to Cumberland's patented antidote for acetaminophen overdose.
The patent is on an acetylcysteine composition that contains no chelating agent. For its Acetadote antidote, Cumberland was asked by the FDA to provide justification for using edetate disodium (EDTA), an ingredient that provides stability that is also known to have negative side effects. In conjunction with Bioniche Pharma Group, Cumberland was able devise a test that showed stability both with and without EDTA. In 2010, Mylan acquired Bioniche and Myland filed its abbreviated new drug application for the generic acetylcysteine about a year after Cumberland's patent was issued. Cumberland then sued Mylan in 2012 and Mylan's defense was that the patent was invalid on the basis that it was derived from a suggestion from someone at the FDA.
As a result of the Federal Circuit decision, Mylan's generic version of the drug could be kept off the market until 2025.
United States Court of Appeals for the Federal Circuit (CAFC), Food and Drug Administration (FDA)
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.